Literature DB >> 30723296

DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer.

Philipp Jurmeister1,2, Anne Schöler3,4, Alexander Arnold5, Frederick Klauschen5,4,6, Dido Lenze5, Michael Hummel5, Leonille Schweizer3,4,6, Hendrik Bläker5, Berit Maria Pfitzner5, Soulafa Mamlouk5,6,7, Christine Sers5,6, Carsten Denkert5,6, Damian Stichel8, Nikolaj Frost9, David Horst5,6, Maximilian von Laffert5,4, David Capper3,6.   

Abstract

Pulmonary enteric adenocarcinoma is a rare non-small cell lung cancer subtype. It is poorly characterized and cannot be distinguished from metastatic colorectal or upper gastrointestinal adenocarcinomas by means of routine pathological methods. As DNA methylation patterns are known to be highly tissue specific, we aimed to develop a methylation-based algorithm to differentiate these entities. To this end, genome-wide methylation profiles of 600 primary pulmonary, colorectal, and upper gastrointestinal adenocarcinomas obtained from The Cancer Genome Atlas and the Gene Expression Omnibus database were used as a reference cohort to train a machine learning algorithm. The resulting classifier correctly classified all samples from a validation cohort consisting of 680 primary pulmonary, colorectal and upper gastrointestinal adenocarcinomas, demonstrating the ability of the algorithm to reliably distinguish these three entities. We then analyzed methylation data of 15 pulmonary enteric adenocarcinomas as well as four pulmonary metastases and four primary colorectal adenocarcinomas with the algorithm. All 15 pulmonary enteric adenocarcinomas were reliably classified as primary pulmonary tumors and all four metastases as well as all four primary colorectal cancer samples were identified as colorectal adenocarcinomas. In a t-distributed stochastic neighbor embedding analysis, the pulmonary enteric adenocarcinoma samples did not form a separate methylation subclass but rather diffusely intermixed with other pulmonary cancers. Additional characterization of the pulmonary enteric adenocarcinoma series using fluorescence in situ hybridization, next-generation sequencing and copy number analysis revealed KRAS mutations in nine of 15 samples (60%) and a high number of structural chromosomal changes. Except for an unusually high rate of chromosome 20 gain (67%), the molecular data was mostly reminiscent of standard pulmonary adenocarcinomas. In conclusion, we provide sound evidence of the pulmonary origin of pulmonary enteric adenocarcinomas and in addition provide a publicly available machine learning-based algorithm to reliably distinguish these tumors from metastatic colorectal cancer.

Entities:  

Mesh:

Year:  2019        PMID: 30723296     DOI: 10.1038/s41379-019-0207-y

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma.

Authors:  Shuhei Teranishi; Chihiro Sugimoto; Hirokazu Nagayama; Wataru Segawa; Atsushi Miyasaka; Shuntaro Hiro; Chihiro Maeda; Hironori Tamura; Nami Masumoto; Yoshinori Nagahara; Nobuyuki Hirama; Nobuaki Kobayashi; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko
Journal:  Cancer Diagn Progn       Date:  2022-03-03

2.  DNA methylation subtypes for ovarian cancer prognosis.

Authors:  Lili Yin; Ningning Zhang; Qing Yang
Journal:  FEBS Open Bio       Date:  2021-02-03       Impact factor: 2.693

3.  Genetic mutation profiles and immune microenvironment analysis of pulmonary enteric adenocarcinoma.

Authors:  Min Xie; Dong Chen; Yong Li; Xiansheng Liu; Dong Kuang; Xiaochen Li
Journal:  Diagn Pathol       Date:  2022-02-16       Impact factor: 2.644

4.  An Integrated Epigenomic and Genomic View on Phyllodes and Phyllodes-like Breast Tumors.

Authors:  Juergen Hench; Tatjana Vlajnic; Savas Deniz Soysal; Ellen C Obermann; Stephan Frank; Simone Muenst
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

5.  A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review.

Authors:  Xiaohu Xu; Dong Chen; Xiao Wu; Qi Wang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

6.  Machine learning analysis of exome trios to contrast the genomic architecture of autism and schizophrenia.

Authors:  Sameer Sardaar; Bill Qi; Alexandre Dionne-Laporte; Guy A Rouleau; Reihaneh Rabbany; Yannis J Trakadis
Journal:  BMC Psychiatry       Date:  2020-02-28       Impact factor: 3.630

Review 7.  Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter?

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Vanessa Dos Reis Ferreira; Paula A Videira; And Gonçalo Valadão
Journal:  Genes (Basel)       Date:  2019-11-27       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.